Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.
Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J. Sehouli J, et al. Among authors: pfisterer j. Eur J Cancer. 2015 May;51(7):825-32. doi: 10.1016/j.ejca.2015.01.008. Epub 2015 Mar 11. Eur J Cancer. 2015. PMID: 25771433
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A, et al. Among authors: pfisterer j. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. doi: 10.1093/jnci/djg036. J Natl Cancer Inst. 2003. PMID: 12953086 Clinical Trial.
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Kommoss F, et al. Among authors: pfisterer j. Gynecol Oncol. 2005 Apr;97(1):195-9. doi: 10.1016/j.ygyno.2004.12.047. Gynecol Oncol. 2005. PMID: 15790458 Clinical Trial.
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Greimel ER, et al. Among authors: pfisterer j. J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E; Arbeitsgemeinschaft Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. du Bois A, et al. Among authors: pfisterer j. J Clin Oncol. 2006 Mar 1;24(7):1127-35. doi: 10.1200/JCO.2005.03.2938. J Clin Oncol. 2006. PMID: 16505432 Clinical Trial.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Pfisterer J, et al. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. doi: 10.1093/jnci/djj296. J Natl Cancer Inst. 2006. PMID: 16882940 Clinical Trial.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Pfisterer J, et al. J Clin Oncol. 2006 Oct 10;24(29):4699-707. doi: 10.1200/JCO.2006.06.0913. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966687 Clinical Trial.
204 results